Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 28

1.

Improving symptom management for people with amyotrophic lateral sclerosis.

Nicholson K, Murphy A, McDonnell E, Shapiro J, Simpson E, Glass J, Mitsumoto H, Forshew D, Miller R, Atassi N.

Muscle Nerve. 2018 Jan;57(1):20-24. doi: 10.1002/mus.25712. Epub 2017 Jul 1.

PMID:
28561886
2.

Phase I clinical trial of safety of L-serine for ALS patients.

Levine TD, Miller RG, Bradley WG, Moore DH, Saperstein DS, Flynn LE, Katz JS, Forshew DA, Metcalf JS, Banack SA, Cox PA.

Amyotroph Lateral Scler Frontotemporal Degener. 2017 Feb;18(1-2):107-111. doi: 10.1080/21678421.2016.1221971. Epub 2016 Sep 2.

PMID:
27589995
3.

Phrenic nerve conduction studies as a biomarker of respiratory insufficiency in amyotrophic lateral sclerosis.

Jenkins JA, Sakamuri S, Katz JS, Forshew DA, Guion L, Moore D, Miller RG.

Amyotroph Lateral Scler Frontotemporal Degener. 2016;17(3-4):213-20. doi: 10.3109/21678421.2015.1112406. Epub 2015 Nov 30.

PMID:
26618854
4.

NP001 regulation of macrophage activation markers in ALS: a phase I clinical and biomarker study.

Miller RG, Zhang R, Block G, Katz J, Barohn R, Kasarskis E, Forshew D, Gopalakrishnan V, McGrath MS.

Amyotroph Lateral Scler Frontotemporal Degener. 2014 Dec;15(7-8):601-9. doi: 10.3109/21678421.2014.951940. Epub 2014 Sep 5.

5.

Seeking a measure of clinically meaningful change in ALS.

McElhiney M, Rabkin JG, Goetz R, Katz J, Miller RG, Forshew DA, David W, Cudkowicz M, Glass JD, Appel S, Simpson E, Mitsumoto H.

Amyotroph Lateral Scler Frontotemporal Degener. 2014 Sep;15(5-6):398-405. doi: 10.3109/21678421.2014.942668. Epub 2014 Aug 15. Erratum in: Amyotroph Lateral Scler Frontotemporal Degener. 2014 Dec;15(7-8):627.

PMID:
25124889
6.

Quality improvement in neurology: amyotrophic lateral sclerosis quality measures. Report of the Quality Measurement and Reporting Subcommittee of the American Academy of Neurology.

Miller RG, Brooks BR, Swain-Eng RJ, Basner RC, Carter GT, Casey P, Cohen AB, Dubinsky R, Forshew D, Jackson CE, Kasarskis E, Procaccini NJ, Sanjak M, Tolin FP.

Amyotroph Lateral Scler Frontotemporal Degener. 2014 Jun;15(3-4):165-8. doi: 10.3109/21678421.2013.875706. Epub 2014 Apr 7. No abstract available.

PMID:
24707820
7.

ALS Multicenter Cohort Study of Oxidative Stress (ALS COSMOS): study methodology, recruitment, and baseline demographic and disease characteristics.

Mitsumoto H, Factor-Litvak P, Andrews H, Goetz RR, Andrews L, Rabkin JG, McElhiney M, Nieves J, Santella RM, Murphy J, Hupf J, Singleton J, Merle D, Kilty M, Heitzman D, Bedlack RS, Miller RG, Katz JS, Forshew D, Barohn RJ, Sorenson EJ, Oskarsson B, Fernandes Filho JA, Kasarskis EJ, Lomen-Hoerth C, Mozaffar T, Rollins YD, Nations SP, Swenson AJ, Shefner JM, Andrews JA, Koczon-Jaremko BA; ALS COSMOS Study Group.

Amyotroph Lateral Scler Frontotemporal Degener. 2014 Jun;15(3-4):192-203. doi: 10.3109/21678421.2013.864312. Epub 2014 Feb 24.

8.

Quality improvement in neurology: amyotrophic lateral sclerosis quality measures: report of the quality measurement and reporting subcommittee of the American Academy of Neurology.

Miller RG, Brooks BR, Swain-Eng RJ, Basner RC, Carter GT, Casey P, Cohen AB, Dubinsky R, Forshew D, Jackson CE, Kasarskis E, Procaccini NJ, Sanjak M, Tolin FP.

Neurology. 2013 Dec 10;81(24):2136-40. doi: 10.1212/01.wnl.0000437305.37850.f9. Epub 2013 Nov 22. Review.

9.

ALS Untangled No. 20: the Deanna protocol.

ALSUntangled Group, Fournier C, Bedlack B, Hardiman O, Heiman-Patterson T, Gutmann L, Bromberg M, Ostrow L, Carter G, Kabashi E, Bertorini T, Mozaffar T, Andersen P, Dietz J, Gamez J, Dimachkie M, Wang Y, Wicks P, Heywood J, Novella S, Rowland LP, Pioro E, Kinsley L, Mitchell K, Glass J, Sathornsumetee S, Kwiecinski H, Baker J, Atassi N, Forshew D, Ravits J, Conwit R, Jackson C, Sherman A, Dalton K, Tindall K, Gonzalez G, Robertson J, Phillips L, Benatar M, Sorenson E, Shoesmith C, Nash S, Maragakis N, Moore D, Caress J, Boylan K, Armon C, Grosso M, Gerecke B, Wymer J, Oskarsson B, Bowser R, Drory V, Shefner J, Lechtzin N, Leitner M, Miller R, Mitsumoto H, Levine T, Russell J, Sharma K, Saperstein D, McClusky L, MacGowan D, Licht J, Verma A, Strong M, Lomen-Hoerth C, Tandan R, Rivner M, Kolb S, Polak M, Rudnicki S, Kittrell P, Quereshi M, Sachs G, Pattee G, Weiss M, Kissel J, Goldstein J, Rothstein J, Pastula D, Gleb L, Ogino M, Rosenfeld J, Carmi E, Oster C, Barkhaus P, Valor E.

Amyotroph Lateral Scler Frontotemporal Degener. 2013 May;14(4):319-23. doi: 10.3109/21678421.2013.788405. Epub 2013 May 2. Review. No abstract available.

PMID:
23638638
10.

Systemic immune system alterations in early stages of Alzheimer's disease.

Zhang R, Miller RG, Madison C, Jin X, Honrada R, Harris W, Katz J, Forshew DA, McGrath MS.

J Neuroimmunol. 2013 Mar 15;256(1-2):38-42. doi: 10.1016/j.jneuroim.2013.01.002. Epub 2013 Feb 4.

11.

Survey of current enteral nutrition practices in treatment of amyotrophic lateral sclerosis.

Zhang M, Hubbard J, Rudnicki SA, Johansen CS, Dalton K, Heiman-Patterson T, Forshew DA, Wills AM.

ESPEN J. 2013 Feb 1;8(1):e25-e28.

12.

Phase II screening trial of lithium carbonate in amyotrophic lateral sclerosis: examining a more efficient trial design.

Miller RG, Moore DH, Forshew DA, Katz JS, Barohn RJ, Valan M, Bromberg MB, Goslin KL, Graves MC, McCluskey LF, McVey AL, Mozaffar T, Florence JM, Pestronk A, Ross M, Simpson EP, Appel SH; WALS Study Group.

Neurology. 2011 Sep 6;77(10):973-9. doi: 10.1212/WNL.0b013e31822dc7a5. Epub 2011 Aug 3.

13.

Gene expression profiling in peripheral blood mononuclear cells from patients with sporadic amyotrophic lateral sclerosis (sALS).

Zhang R, Hadlock KG, Do H, Yu S, Honrada R, Champion S, Forshew D, Madison C, Katz J, Miller RG, McGrath MS.

J Neuroimmunol. 2011 Jan;230(1-2):114-23. doi: 10.1016/j.jneuroim.2010.08.012. Epub 2010 Sep 29.

14.

Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: multidisciplinary care, symptom management, and cognitive/behavioral impairment (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology.

Miller RG, Jackson CE, Kasarskis EJ, England JD, Forshew D, Johnston W, Kalra S, Katz JS, Mitsumoto H, Rosenfeld J, Shoesmith C, Strong MJ, Woolley SC; Quality Standards Subcommittee of the American Academy of Neurology.

Neurology. 2009 Oct 13;73(15):1227-33. doi: 10.1212/WNL.0b013e3181bc01a4. Review.

15.

Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: drug, nutritional, and respiratory therapies (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology.

Miller RG, Jackson CE, Kasarskis EJ, England JD, Forshew D, Johnston W, Kalra S, Katz JS, Mitsumoto H, Rosenfeld J, Shoesmith C, Strong MJ, Woolley SC; Quality Standards Subcommittee of the American Academy of Neurology.

Neurology. 2009 Oct 13;73(15):1218-26. doi: 10.1212/WNL.0b013e3181bc0141. Review. Erratum in: Neurology. 2009 Dec 15;73(24):2134. Neurology. 2010 Mar 2;74(9):781.

16.

A timeline for predicting durable medical equipment needs and interventions for amyotrophic lateral sclerosis patients.

Bromberg MB, Brownell AA, Forshew DA, Swenson M.

Amyotroph Lateral Scler. 2010;11(1-2):110-5. doi: 10.3109/17482960902835970.

PMID:
19412817
17.

The ALSSQOL: balancing physical and nonphysical factors in assessing quality of life in ALS.

Simmons Z, Felgoise SH, Bremer BA, Walsh SM, Hufford DJ, Bromberg MB, David W, Forshew DA, Heiman-Patterson TD, Lai EC, McCluskey L.

Neurology. 2006 Nov 14;67(9):1659-64.

PMID:
17101900
18.

The effects of executive and behavioral dysfunction on the course of ALS.

Olney RK, Murphy J, Forshew D, Garwood E, Miller BL, Langmore S, Kohn MA, Lomen-Hoerth C.

Neurology. 2005 Dec 13;65(11):1774-7.

PMID:
16344521
19.

A survey of clinicians' practice in the symptomatic treatment of ALS.

Forshew DA, Bromberg MB.

Amyotroph Lateral Scler Other Motor Neuron Disord. 2003 Dec;4(4):258-63.

PMID:
14753660
20.

Comparison of instruments addressing quality of life in patients with ALS and their caregivers.

Bromberg MB, Forshew DA.

Neurology. 2002 Jan 22;58(2):320-2.

PMID:
11805269
21.

Electrophysiologic endpoint measures in a multicenter ALS drug trial.

Bromberg MB, Fries TJ, Forshew DA, Tandan R.

J Neurol Sci. 2001 Feb 15;184(1):51-5.

PMID:
11231032
22.

Therapeutic advances: new hope for patients with ALS.

Forshew DA.

Nurs Spectr (Wash D C). 1998 Dec 14;8(25):12-4. Review. No abstract available.

PMID:
10542672
23.

The use of "clinic room" presentation as an educational tool in the ambulatory care setting.

Smith AG, Bromberg MB, Singleton JR, Forshew DA.

Neurology. 1999 Jan 15;52(2):317-20.

PMID:
9932950
24.

Randomized trial of azathioprine or prednisone for initial immunosuppressive treatment of myasthenia gravis.

Bromberg MB, Wald JJ, Forshew DA, Feldman EL, Albers JW.

J Neurol Sci. 1997 Sep 1;150(1):59-62.

PMID:
9260858
25.

A controlled trial of amino acid therapy in amyotrophic lateral sclerosis: I. Clinical, functional, and maximum isometric torque data.

Tandan R, Bromberg MB, Forshew D, Fries TJ, Badger GJ, Carpenter J, Krusinski PB, Betts EF, Arciero K, Nau K.

Neurology. 1996 Nov;47(5):1220-6.

PMID:
8909433
26.

The economic impact of ALS.

Klein LM, Forshew DA.

Neurology. 1996 Oct;47(4 Suppl 2):S126-9.

PMID:
8858069
27.

Individuals with amyotrophic lateral sclerosis are in caloric balance despite losses in mass.

Nau KL, Bromberg MB, Forshew DA, Katch VL.

J Neurol Sci. 1995 May;129 Suppl:47-9.

PMID:
7595619
28.

Motor unit number estimation, isometric strength, and electromyographic measures in amyotrophic lateral sclerosis.

Bromberg MB, Forshew DA, Nau KL, Bromberg J, Simmons Z, Fries TJ.

Muscle Nerve. 1993 Nov;16(11):1213-9.

Supplemental Content

Loading ...
Support Center